Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 1/20 | 0.49 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 3/20 | 0.48 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.47 |
| ▸ | P2RX1 | P51575 | 2/20 | 0.47 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.47 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.47 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.47 |
| ▸ | TMPRSS4 | Q9NRS4 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 6/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | BAZ1A | Q9NRL2 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 3/20 | 0.47 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5142354 | 0.89 | MEN1 (0.54) | KDRRAB9AP2RX1SLC2A1P2RX4 | |
| SCHEMBL5142846 | 0.84 | TP53 (0.50) | KDRRXFP1RAB9AMAPTMEN1 | |
| SCHEMBL5145916 | 0.83 | KDR (0.54) | KDRRXFP1RAB9AP2RX1SLC2A1 | |
| SCHEMBL5142353 | 0.82 | SLC2A1 (0.54) | KDRRAB9AP2RX1SLC2A1P2RX4 | |
| SCHEMBL5142747 | 0.82 | KDR (0.57) | KDRRXFP1RAB9AP2RX1SLC2A1 | |
| SCHEMBL5142676 | 0.80 | CCR2 (0.52) | KDRRXFP1RAB9AMAPTMEN1 | |
| SCHEMBL5142369 | 0.79 | MAPT (0.56) | KDRRXFP1RAB9AP2RX1SLC2A1 | |
| SCHEMBL5145822 | 0.78 | KMT2A (0.50) | KDRRAB9AMAPTMEN1KMT2A | |
| SCHEMBL5142735 | 0.78 | MAPT (0.51) | KDRRAB9AP2RX1SLC2A1P2RX4 | |
| SCHEMBL5142680 | 0.78 | MAPT (0.54) | KDRRXFP1RAB9AP2RX1SLC2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070043076-A1 | Substituted 2-arylmethylene-n-aryl-n'aryl-malonamides and analogs as activators of caspases and inducers of apoptosis | CYTOVIA, INC. | 2007-02-22 | — | — | US | claimed |
| WO-2005037196-A2 | SUBSTITUTED 2-ARYLMETHYLENE-N-ARYL-N'-ARYL-MALONAMIDES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS | CYTOVIA, INC. (US) | 2005-04-28 | — | — | WO | claimed |
| US-20070043076-A1 | Substituted 2-arylmethylene-n-aryl-n'aryl-malonamides and analogs as activators of caspases and inducers of apoptosis | CYTOVIA, INC. | 2007-02-22 | — | — | US | disclosed |
| WO-2005037196-A2 | SUBSTITUTED 2-ARYLMETHYLENE-N-ARYL-N'-ARYL-MALONAMIDES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS | CYTOVIA, INC. (US) | 2005-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043076-A1 | Substituted 2-arylmethylene-n-aryl-n'aryl-malonamides and analogs as activators of caspases and inducers of apoptosis | CASP14, CASP2, CASP3 | KDR 2936/4885RXFP1 4875/4885RAB9A 1979/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.